Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients

BMC Anesthesiology

Volumn 11, Issue , 2011, Pages

  Roberts, Jason A ^a,b   Roberts, Michael S ^a,c   Semark, Andrew ^b   Udy, Andrew A ^a,b   Kirkpatrick, Carl M J ^a   Paterson, David L ^b,d   Roberts, Matthew J ^a   Kruger, Peter ^a,e   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; INDOCYANINE GREEN; PIPERACILLIN PLUS TAZOBACTAM; SODIUM BROMIDE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CRITICAL ILLNESS; DRUG INFUSION; DRUG PENETRATION; HEART OUTPUT MEASUREMENT; HUMAN; INJURY; INTENSIVE CARE UNIT; INTERSTITIAL FLUID; KIDNEY FUNCTION TEST; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; SEPSIS; URINALYSIS;

EID: 79951562557     PISSN: None     EISSN: 14712253     Source Type: Journal    
DOI: 10.1186/1471-2253-11-3     Document Type: Article

References (50)

1. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004, 30(4):589-96. 10.1007/s00134-004-2157-0, 14963646.
2. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115(2):462-74. 10.1378/chest.115.2.462, 10027448.
3. Roberts JA, Lipman J. Antibiotic dosing in intensive care: Pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45(8):755-773. 10.2165/00003088-200645080-00001, 16884316.
4. van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks A. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999, 21(1):63-73. 10.1097/00007691-199902000-00010, 10051056.
5. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993, 37(5):1073-81. 187901, 8517694.
6. Scaglione F, Esposito S, Leone S, Lucini V, Pannacci M, Ma L, Drusano GL. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J 2009, 34(2):394-400. 10.1183/09031936.00149508, 19213786.
7. Roberts JA, Ulldemolins M, Roberts MS, McWhinney BC, Ungerer JPJ, Paterson DL, Lipman J. Therapeutic Drug Monitoring of Beta-lactams in Critically Ill Patients: Proof of concept. Int J Antimicrob Agents 2010, 36(4):332-9. 10.1016/j.ijantimicag.2010.06.008, 20685085.
8. Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eichler HG, Müller M. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001, 29:385-391. 10.1097/00003246-200102000-00030, 11246321.
9. Khol BA, Deutschman CS. The inflammatory response to surgery and trauma. Curr Opin Crit Care 2006, 12(4):325-32. 10.1097/01.ccx.0000235210.85073.fc, 16810043.
10. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101(6):1644-55. 10.1378/chest.101.6.1644, 1303622.
11. Parillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Int Med 1990, 113(3):227-42.
12. Brown R, Babcock R, Talbert J, Greunenberg J, Czurak C, Cambell M. Renal function in the critically ill pot-operative patients: sequential assessment of creatinine osmolar and free water clearance. Crit Care Med 1980, 8(2):68-72. 10.1097/00003246-198002000-00004, 7353390.
13. Loirat P, Rohan J, Baillet A, Beaufils F, David R, Chapman A. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Engl J Med 299(17):915-9. 10.1056/NEJM197810262991703, 692596.
14. Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern Med J 2010,
15. Hoste EA, Damen J, Vanholder RC, Norbert H, Lameire JR, Van den Hauwe KD, Colardyn FA. Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrol Dial Transplant 2005, 20(4):747-53. 10.1093/ndt/gfh707, 15701668.
16. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented Renal Clearance: Implications for Antibacterial Dosing in the Critically III. Clin Pharmacokinet 2010, 49(1):1-16. 10.2165/11318140-000000000-00000, 20000886.
17. Lipman J, Wallis SC, Rickard CM, Fraenkel D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001, 27(2):363-70. 10.1007/s001340000741, 11396280.
18. Young RJ, Lipman J, Gin T, C D Gomersall CD, Joynt GM, Oh TE. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicro Chemother 1997, 40(2):269-73.
19. MacArthur RD, Miller M, Albertson T, Panacek E, Johnson D, Teoh L, Barchuk W. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS Trial. Clin Infect Dis 2004, 15(2):284-8.
20. Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic Resistance - What's dosing got to do with it?. Crit Care Med 2008, 36(8):2433-40. 10.1097/CCM.0b013e318180fe62, 18596628.
21. Poggio ED, Nef PC, Wang X, Greene T, Van Lente F, Dennis VW, Ha PM. Performance of the Cockcrof-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 2005, 46(2):242-52. 10.1053/j.ajkd.2005.04.023, 16112042.
22. Snider RD, Kruse JA, Bander JJ, Dunn GH. Accuracy of estimated creatinine clearance in obese patients with stable renal function in the intensive care unit. Pharmacotherapy 1995, 15(6):747-53.
23. Buclin T, Pechere-Bertschi A, Sechaud R, Decosterd LA, Munafo A, Burnier M, Biollaz J. Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method. J Clin Pharmacol 1997, 37(8):679-92.
24. Triginer C, Izquierdo I, Fernandez R, Rello J, Torrent J, Benito S, Net A. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990, 16(5):303-6. 10.1007/BF01706354, 2212254.
25. Gosling P, Sanghera K, Dickson G. Generalized vascular permeability and pulmonary function in patients following serious trauma. J Trauma 1994, 36:477-81. 10.1097/00005373-199404000-00002, 8158705.
26. Marik PE, Havlik I, Monteagudo FSE, Lipman J. The pharmacokinetics of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. J Antimicrob Chemother 1991, 27(suppl C):81-89.
27. Plank LD, Monk DN, Woollard GA, Hill GL. Evaluation of multifrequency bioimpedance spectroscopy for measurement of the extracellular water space in critically ill patients. Appl Radiat Isot 1998, 49(5-6):481-3. 10.1016/S0969-8043(97)00060-2, 9569521.
28. Cheng AT, Plank LD, Hill GL. Prolonged overexpansion of extracellular water in elderly patients with sepsis. Arch Surg 1998, 133(7):745-51. 10.1001/archsurg.133.7.745, 9688003.
29. Plank LD, Hill GL. Similarity of changes in body composition in intensive care patients following severe sepsis or major blunt injury. Ann NY Acad Sci 2000, 904:592-602. 10.1111/j.1749-6632.2000.tb06521.x, 10865810.
30. Jaehde U, Sorgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995, 29(1):15-28. 10.2165/00003088-199529010-00003, 7586895.
31. Finfer S, Bellomo R, Boyce N, French J, Myburg J, Norton R, . SAFE study investigators A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004, 350(22):2247-2256. 10.1056/NEJMoa040232, 15163774, SAFE study investigators.
32. Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999, 43(10):2559-61. 89521, 10508045.
33. Roberts JA, Paratz JD, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections - a review of its role. Int J Antimicrob Agents 2007, 30(1):11-8. 10.1016/j.ijantimicag.2007.02.002, 17442541.
34. Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother 1993, 31(Suppl D):1-16.
35. Busse MW, Zisowshy S, Henschen S, Panning B, Piepenbrock B. Plasma volume estimation using indocyanine green. A single intravenous injection method. Anaesthesia 1993, 48(1):41-3. 10.1111/j.1365-2044.1993.tb06789.x, 8434747.
36. Wong WW, Sheng HP, Morkeberg JC, Kosanovich JL, Clarke LL, Klein PD. Measurement of extracellular water volume by bromide ion chromatography. Am J Clin Nutr 1989, 50:1290-1294.
37. Monk DN, Plank LD, Franch-Arcas G, Finn PJ, Streat SJ, Hill GL. Sequential changes in the metabolic response in critically injured patients during the first 25 days after blunt trauma. Ann Surg 1996, 223:395-405. 10.1097/00000658-199604000-00008, 1235135, 8633918.
38. Buclin T, Sechaud R, Bertschi AP, Decosterd LA, Belaz N, Appenzeller M, Burnier M, Biollaz J. Estimation of glomerular filtration rate by sinistrin clearance using various approaches. Ren Fail 1998, 20(2):267-76. 10.3109/08860229809045111, 9574452.
39. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis-Bolus versus continuous administration. Crit Care Med 2009, 37(3):926-933. 10.1097/CCM.0b013e3181968e44, 19237898.
40. Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction - intermittent bolus vs continuous administration? Monte-Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-50. 10.1093/jac/dkp139, 19398460.
41. Cherry RA, Eachempati SR, Hydo L, Barie PS. Accuracy of short-duration creatinine clearance determinations in predicting 24-hour creatinine clearance in critically ill and injured patients. J Trauma 2002, 53(2):267-71. 10.1097/00005373-200208000-00013, 12169932.
42. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of Lean Bodyweight. Clinical Pharmacokinetics 2005, 44(10):1051-1065. 10.2165/00003088-200544100-00004, 16176118.
43. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41. 10.1159/000180580, 1244564.
44. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
45. Antonelli M, Moreno R, Vincent JL. Application of SOFA score to trauma patients. Sequential Organ Failure Assessment. Intensive Care Med 1999, 25:389-394. 10.1007/s001340050863, 10342513.
46. Champion HR, Sacco WJ, Copes WS, Gann DS, Gennarelli TA, Flanagan ME. A revision of the Trauma Score. J Trauma 1989, 29(5):623-629. 10.1097/00005373-198905000-00017, 2657085.
47. Zeitlinger BS, Zeitlinger M, Leitner I, Müller M, Joukhadar C. Clinical Scoring System for the Prediction of Target Site Penetration of Antimicrobials in Patients with Sepsis. Clinical Pharmacokinetics 2007, 46(1):75-83. 10.2165/00003088-200746010-00004, 17201459.
48. Faul F, Erdfelder E, Lang A, Buchner A. Gpower 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007, 39:175-19. 10.3758/BF03193146, 17695343.
49. Roos JF, Lipman J, Kirkpatrick CM. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med 2007, 33(5):781-8. 10.1007/s00134-007-0573-7, 17342515.
50. Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006, 58(5):987-93. 10.1093/jac/dkl349, 16943209.